STAR Pharmaceutical Limited provided unaudited group earnings guidance for the fourth quarter ended December 31, 2017. For the period, the company expects to record a significant drop in its revenue and report an operating loss for the fourth quarter of 2017. The significant drop in revenue for the fourth quarter of 2017 was mainly attributed to impairment loss of research and development project funds during the fourth quarter of 2017.